Now showing items 3841-3843 of 3843
Targeting MCL-1 and BCL-2 with polatuzumab vedotin and venetoclax overcomes treatment resistance in R/R non-Hodgkin lymphoma: Results from preclinical models and a Phase Ib study
(John Wiley & Sons, Inc., 2023-03)
The treatment of patients with relapsed or refractory lymphoid neoplasms represents a significant clinical challenge. Here, we identify the pro-survival BCL-2 protein family member MCL-1 as a resistance factor for the BCL-2 ...
Reproductive Impact of Testosterone Therapy in a Transgender Mouse Model
(2024)
Long-term gender-affirming testosterone (T) therapy may negatively impact reproductive capacity for transgender men transitioning from female to male. Given clinical guidelines assuming fertility loss and anecdotal evidence ...
Machine Learning Guided Drug Discovery: Comprehensive Application in Janus Kinase Inhibitor Design
(2023)
Conventional drug discovery is often plagued by resource-intensive processes, leading to significant attrition rates due to challenges such as efficacy shortcomings, safety concerns and suboptimal pharmacokinetics (PK). ...